New highs every day, but weak, and on low volume.
Buying cheap is the way to go with these, so I skipped STPFQ and XIDEQ this year, though OSGIQ was cheap @ $4.50 in Dec. Last year, I was in EKDKQ, PCXCQ, AONEQ, and ATPAQ, and they all ran, though 3 ran too late for me, as my patience ran out and I sold beforehand. ATPAQ was a 10-bagger from its bottom last March.
Shorts (or whoever has been keeping a lid on the surges) haven't been driving price down from the surges like before. They may give up soon on trying to hold back the surges as their shorting capacity is overwhelmed in light of a seemingly inevitable price spike.
I've seen so many of these forgotten Q stocks roar from the bottom. I've got a list of them with daily prices and charts, but too much a hassle to dig up to post here. Other good candidates are ATPAQ and VELTF.
Exactly how has Butamax kept Gevo's Luverne plant from functioning?
Link? Doesn't show in Think or Swim, and I can't find in search of MIP-1095. I'm #$%$ if company allowed news to leak in Germany without press release.
That website doesn't even show true volume traded. For instance, yesterday, it showed over a million shares less than was actually traded. I really don't see its usefulness. What does it matter whether one knows how much of the trading was new short selling? The price and volume tells the story. It's clear that the price has been manipulated, probably by shorts. It's obvious when volume is low, there is no manipulative pressure; whereas, there is little movement with high volume. Shorts are probably trying to keep a lid on it, but I've seen such patterns in other stocks many times, and it is not predictive of what will happen later. Often, at some point, regardless of news, the lid is blown off. By the way, it's "our way," not "are way," and "inflection," not "reflection."
Nothing new. And those Street ratings are all based solely on income/financials without accounting for other relevant issues (e.g. Luverne plant producing commercial quantity, partnerships, patents/legal, etc.)
The vote will be on authorization for RS over the next year. Since IVAN will be getting a 6 month listing extension this week, there will be no need to implement a RS unless and until IVAN isn't above $1 by the end of that extension.
What does the price mean? Weren't the RSUs granted (i.e. free)? Are they then sold at market price?
Dude, it's not late. I doubt that it was ever scheduled for 3/3. It's an annual report. They have til 3/31 to file (without extension), and there's no advantage to filing earlier. Annual reports are a lot of work. Sometimes, other things take priority than filing earlier than necessary. Hopefully, they are good things for the company/investors.
You make no sense. There's only one AdCom date. It was March 10, but canceled due to weather. It cannot be simultaneously March and June.
I searched on your site and found the last mention of PGNX on Jan. 29, which only commented on the big drop after the "big news" of 2 deaths in the study results of the prostate ADC. Fool me once, shame on you. I won't look at your site again.
How is a $40/share buy-and-hold a profit, even at $7/share?